Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for diabetic macular edema – retinal leakage in real-world Chinese practice
ChiCTR2600122561Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Beijing Tongren Hospital. Primary endpoint: Panretinal Leakage Index at week 12. Started Apr 2026; status: recruiting.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2600122561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122561.